- List
- By Topic
- On Map
- Search Details

"WDHA syndrome"
Need help? See RSS Feeds
Choose a feed type:

"WDHA syndrome" (16 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT00131911 | Completed Has Results |
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
93 | All | 18 Years and older (Adult, Senior) | NCT00131911 | NCI-2009-00121 MC044H 7046 CDR0000437792 N01CM62205 |
June 2005 | October 2010 | April 2013 | August 19, 2005 | November 17, 2014 | November 17, 2014 |
|
|
2 | NCT00075439 | Completed | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
|
|
Interventional | Phase 2 |
|
NIH |
|
|
90 | All | 18 Years and older (Adult, Senior) | NCT00075439 | NCI-2012-02796 MC0279 N01CM62205 |
December 2003 | May 2007 | January 12, 2004 | June 4, 2013 |
|
|||
3 | NCT00004074 | Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
|
|
Interventional | Phase 1 |
|
NIH |
|
|
15 | All | 18 Years and older (Adult, Senior) | NCT00004074 | NCI-2012-01398 99H0185 U01CA076576 CDR0000067282 |
August 1999 | February 2009 | October 29, 2003 | February 28, 2013 |
|
|||
4 | NCT00454376 | Unknown † | Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors |
|
|
Observational |
|
NIH |
|
408 | All | 18 Years and older (Adult, Senior) | NCT00454376 | CDR0000537344 EORTC-QLQ-G.I.NET21 EU-20712 BNHFT-P4NET EU-207101 |
October 2006 | March 30, 2007 | October 29, 2013 |
|
||||||
5 | NCT00416767 | Completed | Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery |
|
|
Interventional | Phase 2 |
|
Other |
|
20 | All | 18 Years to 80 Years (Adult, Senior) | NCT00416767 | CDR0000453858 FFCD-0302 EU-20544 PFIZER-FFCD-0302 |
May 2004 | January 2006 | July 2007 | December 28, 2006 | May 30, 2016 | ||||
6 | NCT00538850 | Completed Has Results |
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain |
|
|
Interventional | Phase 3 |
|
Industry / NIH |
|
|
130 | All | 18 Years and older (Adult, Senior) | NCT00538850 | INS-05-001 CDR0000581128 |
October 2007 | February 2010 | October 2010 | October 3, 2007 | March 5, 2014 | March 5, 2014 |
|
|
7 | NCT00466856 | Terminated | Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
10 | All | 18 Years and older (Adult, Senior) | NCT00466856 | VICC GI 0365 VU-VICC-GI-0365 |
December 2003 | October 2006 | October 2007 | April 27, 2007 | May 18, 2012 |
|
||
8 | NCT00427349 | Completed Has Results |
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
|
46 | All | 18 Years and older (Adult, Senior) | NCT00427349 | CDR0000526256 ECOG-E4206 U10CA023318 |
September 2008 | October 2014 | April 2015 | January 29, 2007 | August 12, 2016 | June 4, 2015 |
|
|
9 | NCT00227617 | Unknown † | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors |
|
|
Interventional | Phase 2 Phase 3 |
|
Other / NIH / Industry |
|
|
70 | All | 18 Years and older (Adult, Senior) | NCT00227617 | 04458 P30CA082103 UCSF-04458 |
June 2005 | January 2012 | June 2016 | September 28, 2005 | April 9, 2015 |
|
||
10 | NCT00227773 | Withdrawn | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
0 | All | 18 Years to 120 Years (Adult, Senior) | NCT00227773 | CDR0000446076 ECOG-E6203 |
September 28, 2005 | October 8, 2015 | |||||||
11 | NCT00096083 | Completed | Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer |
|
|
Interventional | Phase 2 |
|
Industry / NIH |
|
|
56 | All | 16 Years and older (Child, Adult, Senior) | NCT00096083 | CDR0000391827 NCI-04-C-0273 NCI-6332 DELCATH-G990039 |
September 2004 | August 2012 | August 2012 | November 9, 2004 | October 23, 2013 |
|
||
12 | NCT00005842 | Completed | Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer |
|
|
Interventional | Phase 1 |
|
NIH |
|
24 | All | 18 Years and older (Adult, Senior) | NCT00005842 | CDR0000067858 UTHSC-IDD-99-26 SACI-IDD-99-26 NCI-62 |
June 2000 | February 2004 | April 26, 2004 | February 11, 2013 |
|
||||
13 | NCT00006368 | Completed | Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer |
|
|
Interventional | Phase 1 |
|
Industry |
|
60 | All | 18 Years and older (Adult, Senior) | NCT00006368 | NOVARTIS-SMT-B151 MCC-12275 MCC-IRB-5473 CDR0000068241 NCI-G00-1857 |
January 1998 | November 2003 | November 2003 | April 2, 2004 | May 1, 2013 |
|
|||
14 | NCT00005860 | Completed | Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum |
|
|
Interventional | Phase 1 |
|
Other / NIH |
|
All | 18 Years and older (Adult, Senior) | NCT00005860 | CDR0000067890 MSKCC-99100 NCI-T99-0107 |
April 2000 | April 2, 2004 | April 26, 2011 |
|
||||||
15 | NCT00002947 | Terminated | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer |
|
|
Interventional | Phase 1 |
|
Other / NIH |
|
35 | All | 18 Years and older (Adult, Senior) | NCT00002947 | CDR0000065414 YALE-HIC-9041 NCI-G97-1154 |
October 1996 | August 2004 | August 2004 | March 26, 2004 | July 2, 2014 |
|
|||
16 | NCT00027638 | Completed | Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors |
|
|
Interventional | Phase 2 |
|
Other / NIH |
|
All | Child, Adult, Senior | NCT00027638 | MSKCC-01027 CDR0000069051 NCI-G01-2029 |
March 2001 | December 2003 | December 2003 | January 27, 2003 | June 18, 2013 |
|
† Study has passed its completion date and status has not been verified in more than two years.